Pfizer (NYSE:PFE) says the FDA approved the company’s second biosimilar to Johnson & Johnson’s (NYSE:JNJ) best-selling Remicade rheumatoid arthritis drug.
PFE says its Ixifi was approved for all eligible indications of Remicade, including the treatment of Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.
With the approval, Ixifi joins other biosimilars that have claimed market share from Remicade, including PFE’s Inflectra launched in late 2016; PFE says it is evaluating its strategic options for Ixifi as it continues to commercialize Inflectra in the U.S.
